Skip to main content
. 2020 Sep 16;16(9):e1008857. doi: 10.1371/journal.ppat.1008857

Fig 4. The in vivo protection by genotype C1 EV-A71-neutralizing MAbs.

Fig 4

The hSCARB2-transgenic mice were administered with 16-2-11B, 17-1-12A, and 16-3-4D at 10 mg per Kg 24 hours prior to a lethal challenge of genotype C1 EV-A71 TW-5011-2018 (n = 3 per group). Weight change following infection and survival rate were measured. Non-neutralizing anti-EV-A71 canyon MAb 16-2-12D and anti-avian influenza H7 MAb 3A-44 were human IgG controls. The weight data are presented as the means ± standard error of the mean and the comparison of weight change among groups was analyzed using one-way ANOVA followed by Tukey’s post hoc analysis. *, p < 0.05; **, p < 0.01; ***, p < 0.001. d.p.i, day post infection.